CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab Mar 08, 2021 6:00am EST
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19 Mar 06, 2021 8:40pm EST
CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil Mar 05, 2021 6:29pm EST
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab Mar 05, 2021 5:47pm EST
CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients Feb 22, 2021 6:00am EST
Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use Jan 29, 2021 4:01pm EST
REMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries Jan 04, 2021 6:00am EST
CytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity Dec 31, 2020 12:48am EST
FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients Dec 30, 2020 11:38pm EST
